The addition of daratumumab to a conventional regimen is associated with a 2-fold increase in PFS in patients with newly diagnosed multiple myeloma who are ineligible for transplant.

News

The addition of daratumumab to a conventional regimen is associated with a 2-fold increase in PFS in patients with newly diagnosed multiple myeloma who are ineligible for transplant.
Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression.

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma, published in Supportive Care in Cancer (online November 7, 2017; doi:10.1007/s00520-017-3948-5).

Read More

The International Myeloma Foundation (IMF)–the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure–has issued a statement calling a report by the Institute for Clinical and Economic Review (ICER) on the value of myeloma drugs overly simplistic and one that could limit patient access to optimal treatments.

Read More

Subscribe to Multiple Myeloma